Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19996621 | 1.00 | THRB (0.45) | THRBCYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL5985695 | 0.88 | TDP1 (0.40) | THRBCYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL11547378 | 0.88 | TDP1 (0.40) | THRBCYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL455306 | 0.82 | THRB (0.41) | THRBCYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL9687419 | 0.81 | TRIM24 (0.42) | CYP2C19PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9957309 | 0.81 | THRB (0.41) | THRBCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL29090337 | 0.81 | THRB (0.41) | THRBCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL1795613 | 0.79 | — | — | |
| Methacrylic Acid SCHEMBL28177773 | 0.79 | THRB (0.38) | THRBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL450583 | 0.77 | THRB (0.38) | THRBCYP3A4CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3581577-B1 | 15-OXOSTEROID COMPOUND AND METHOD FOR PRODUCING SAME | ASKA PHARM CO LTD (JP) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023173417-A1 | QUANTUM DOT MIXTURE, QUANTUM DOT LIGHT-EMITTING LAYER AND MANUFACTURING METHOD | 京东方科技集团股份有限公司 | 2023-09-21 | — | — | WO | disclosed |
| US-10815268-B2 | 15-oxosteroid compound and process for producing the same | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2020-10-27 | — | — | US | disclosed |
| EP-0679152-B1 | ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES | COSMOS PHARM CORP (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0679152-A1 | ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES. | LAFOR LAB LTD (US) | 1995-11-02 | — | — | EP | disclosed |
| WO-1994015900-A1 | ANTI-ANDROGENIC CYCLO AND BICYCLO ALKENES | LAFOR LABORATORIES LIMITED (US) | 1994-07-21 | — | — | WO | disclosed |
| US-5264619-A | Anti-androgenic cyclo and bicyclo alkenes | LAFOR LABORATORIES LIMITED (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0364470-A1 | ALICYCLIC COMPOUNDS | BTG INTERNATIONAL LIMITED (GB) | 1990-04-25 | — | — | EP | disclosed |
| WO-1988009786-A1 | ALICYCLIC COMPOUNDS AND THEIR CONTRACEPTIVE USE | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-12-15 | — | — | WO | disclosed |
| US-4005029-A | Laundering adjunct | THE PROCTER & GAMBLE COMPANY (US) | 1977-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815268-B2 | 15-oxosteroid compound and process for producing the same | HSD17B7, HSD11B1, HSD11B2 | THRB 199/4885CYP3A4 109/4885CYP2C9 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.